CN102552852A - Pharmaceutical composition and use thereof - Google Patents
Pharmaceutical composition and use thereof Download PDFInfo
- Publication number
- CN102552852A CN102552852A CN2012100243786A CN201210024378A CN102552852A CN 102552852 A CN102552852 A CN 102552852A CN 2012100243786 A CN2012100243786 A CN 2012100243786A CN 201210024378 A CN201210024378 A CN 201210024378A CN 102552852 A CN102552852 A CN 102552852A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- group
- berberine
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of medicine and especially relates to a pharmaceutical composition and a use thereof. The pharmaceutical composition has effects of reducing blood fat and blood sugar. The pharmaceutical composition comprises herb of spanishneedles, berberine, red sage root, pseudo-ginseng, stiff silkworm powder, rhizoma atractylodis, dry ginger and cassia bark. A result of a pharmacodynamical experiment shows that the pharmaceutical composition has good effects of reducing blood fat and blood sugar.
Description
Technical field
The invention belongs to medical technical field, the pharmaceutical composition that be specifically related to have blood sugar lowering, blood fat reducing etc. acts on.
Background technology
Diabetes are commonly encountered diseases, frequently-occurring disease, and its number of patients is just along with the change of the raising of living standards of the people, the aging of population, life style and improving of diagnostic techniques and increase sharply.And prolonged illness can cause the multisystem infringement, causes the chronic progressive external pathological changes of tissues such as eye, kidney, nerve, heart, blood vessel, causes functional defect and depletion.Diabetes spp is in the traditional Chinese medical science " diabetes " category.Chinese medicine thinks that the etiology and pathogenesis of diabetes is mainly that eating and drinking without temperance, disorder of emotion, labor are desired excessively, innate deficiency etc., and causing cloudy body fluid deficiency consumption, scorching inclined to one side Sheng, the deficiency of YIN be this, scorchingly is mark, delays like the state of an illness, can cause deficiency of both QI and YIN or deficiency of both YIN and YANG; Blood stasis, damp and hot, phlegm-damp, diseases caused by retention of fluid are its common pathological products, and these pathological products can become new paathogenic factor again, further increase the weight of the diabetes state of an illness.
Diabetes can be involved trunk and blood capillary with PD, merge like many complication such as hypertension, coronary heart disease, retinopathy, diabetic foot, serious threat human health and life.Wherein diabetes merge dyslipidemia, are to cause one of fatty liver, atherosclerosis, the pathogenetic main hazard factor of coronary heart disease cerebrovascular.Diabetes merge disorders of lipid metabolism and more and more obtain the academia attention, and second international molecule diabetes meeting in 2000 even proposition " glycolipid is sick " said, is intended to stress the critical role of disorders of lipid metabolism in sugared evolution.Development along with Chinese medicine; The understanding that merges dyslipidemia for diabetes is day by day goed deep into; At present Chinese medicine uses single medicinal material and extract thereof, compound treatment primary disease more, compares significantly blood lipid regulation with Western medicine, and the while can also be regulated the unusual performance of body; And have no side effect mostly, obtained good efficacy clinically.Therefore; The research of the dyslipidemia of TCM treatment of diabetes merging from now on should be established unified differentiation of symptoms and signs for classification of syndrome standard under instruction of Chinese Medicine theory, make great efforts to absorb modern medicine to unusual newest research results; The two is combined effectively; Improve the science of scientific research and design, strengthen the credibility of clinical research, the Therapeutic Method of oneself effective single medicine and compound recipe is further screened; Strive for accomplishing that curative effect is lasting, reliable, make the Chinese medicine diabetes merge dyslipidemia and obtain bigger achievement.
Summary of the invention
For these reasons; The applicant is the basis with the theory of Chinese medical science; In conjunction with clinical experience, Herba Bidentis Bipinnatae, berberine, Radix Salviae Miltiorrhizae, Radix Notoginseng, Bombyx Batryticatus powder, Rhizoma Atractylodis, Rhizoma Zingiberis and Cortex Cinnamomi are carried out organic compatibility, obtain new pharmaceutical composition; Pharmacological testing shows that pharmaceutical composition of the present invention has good blood fat reducing and hypoglycemic effect.
The present invention realizes through following technical proposals.
A kind of pharmaceutical composition, pharmaceutical composition is made up of following raw material: Herba Bidentis Bipinnatae, berberine, Radix Salviae Miltiorrhizae, Radix Notoginseng, Bombyx Batryticatus powder, Rhizoma Atractylodis, Rhizoma Zingiberis and Cortex Cinnamomi.
Preferred pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-10 weight portion, berberine 0.1-1 weight portion, Radix Salviae Miltiorrhizae 3-10 weight portion; Radix Notoginseng 1-5 weight portion, Bombyx Batryticatus powder 0.5-5 weight portion, Rhizoma Atractylodis 1-8 weight portion; Rhizoma Zingiberis 1-8 weight portion, Cortex Cinnamomi 0.5-5 weight portion.
Preferred pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 5-7 weight portion, berberine 0.4-0.5 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion; Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
Preferred pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 2-3 weight portion, Rhizoma Atractylodis 5-7 weight portion; Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
Preferred pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion; Rhizoma Zingiberis 5-7 weight portion, Cortex Cinnamomi 2-3 weight portion.
Above-mentioned described pharmaceutical composition is that feedstock production becomes to comprise dosage forms such as oral formulations.
The application of aforementioned pharmaceutical compositions in preparation treatment high blood cholesterol drug.
The application of aforementioned pharmaceutical compositions in the medicine of preparation treatment diabetes.
Above-mentioned said oral formulations includes but not limited to tablet, capsule, granule, oral liquid, mixture or pill.
One, pharmacological testing research
The following test of the present invention is on the test of many times basis, the test that claimed technical scheme is carried out according to the present invention.
1 experiment material
1.1 receive reagent thing and control drug
Receive the reagent thing: see table 1:
Method for preparing: said medicine (removing berberine) is added 8 times of water extraction of medical material weight 2 hours, behind the extracting solution concentrate drying,, subsequent use with the berberine mix homogeneously.Berberine: berberine hydrochloride (Guangdong Huanan Pharmaceutical Co., Ltd).
Control drug: rosiglitazone maleate sheet, GlaxoSmithKline PLC (Tianjin) company limited (lot number: 08070167).
1.2 laboratory animal
SPF level male SD rat (80-120g) is purchased the Experimental Animal Center in Traditional Chinese Medicine University Of Guangzhou, and credit number is SCXK (Guangdong) 2003-0001.
1.3 key instrument and reagent
Electronic balance (the two outstanding Group Co.,Ltd of the U.S.); BS110S electronic balance (Sartorius company); Hot water constant temperature groove (Shanghai Yiheng Scientific Instruments Co., Ltd); Digital electronic clinical thermometer (Fuda, Shenzhen health Industrial Co., Ltd.); TG-16W desk centrifuge (Hunan, Changsha intelligence centrifuge company limited); RT-2100C ELIASA (Five continents, Beijing east development in science and technology company limited); The automatic non-invasive blood pressure test macro in clematis stem road (IITC65-12Manual Scanner, IITC INC., USA); The accurate pipettor of big dragon; Vortex mixer (the special Analytical Instrument Co., Ltd of Shanghai fine jade);-80 ℃ of ultra cold storage freezers (SANYO).
Streptozotocin STZ (
S0130-500MG, lot number 1000712061); Citric acid and sodium citrate (Sigma C1909); Luo Shi
superior blood glucose meter (ACCU-CHZK) and blood sugar test paper are all purchased in company of Switzerland Roche Group; Anhydrous glucose (lot number 20080905) is purchased good fortune chemical reagent in the morning factory in Tianjin; Glucose assays test kit (lot number 20100502) is purchased the glad biotechnology research of the section institute in Shanghai; T-CHOL is measured test kit (lot number 090304), and triglyceride determination test kit (lot number 2010002) is all purchased the remittance power Bioisystech Co., Ltd in Changchun; Flesh/hepatic glycogen test kit (lot number 20101126), free fatty (lot number 20101213) are all purchased and are built up bio-engineering research institute in Nanjing.
2 experimental techniques
2.1 reagent preparation
0.1mol/L citric acid one sodium citrate buffer solution compound method: take by weighing the 2.10g citric acid, being dissolved in 100ml does not have in the ion sterilized water and dissolves, and is made into 0.1mol/L citric acid solution A.Take by weighing the 2.94g sodium citrate, being dissolved in 100ml does not have in the ion sterilized water, is made into 0.1mol/L sodium citrate solution B.By A liquid: B liquid is made into the citric acid-sodium citrate buffer by 1: 1.2 mixed.PH meter is measured pH value, and adjusting pH is 4.2-4.5, and 4 ℃ of cold preservations are subsequent use.
STZ solution compound method: take by weighing a certain amount of STZ, be mixed with 2% concentration with 0.1mol/L citric acid-sodium citrate buffer, about adjust pH to 4.20, operation is all carried out in ice bath.
2.2 animal model
The rat adaptability was fed after 3 days, randomly drawed 10 rats and fed to normal diet as the normal control group.Remaining rat gives high lipid food, and the feeding amount is not limit.All rats are freely drunk distilled water, and room temperature 22-28 ℃, natural lighting is weighed weekly.The rat of high fat diet group gives sunflower seed every other day, feeds for 12 weeks continuously, the body weight of set time monitoring rat weekly during the nursing.After feeding for 12 weeks, with not becoming fat rat to carry out the modeling of STZ lumbar injection, fasting can't help water and is spent the night, the STZ citrate buffer solution of lumbar injection 25mg/kg, and normal control group lumbar injection is with the citrate buffer solution of volume.After 7 days, overnight fasting, tail vein are got blood and are surveyed fasting glucose, and rat whole blood blood glucose value >=11.0mmol/L is classified as diabetes model.
2.3 feed formula
High lipid food prescription: 50% normal diet, 15% casein, 5% Semen arachidis hypogaeae, 10% yolk powder, 12% Adeps Sus domestica, 5% sucrose, 1% Oleum Sesami, 2% Sal, 10/50kg of cod-liver oil.Feedstuff is processed by Guangdong Medical Lab Animal Center.
Normal diet: provide by Beijing section Australia feed corporation,Ltd that pulls together.
2.4 grouping administration
Obese rat is divided into five groups at random, i.e. 1. model group, and 2. positive drug Avandia group, 3. prescription 1, and 4. prescription 2, and 5. prescription 3; Dosage (seeing table 2) confirms that according to " pharmacological experimental methodology " formula the dosage of compound medicine and Avandia all is equivalent to 5 times of people's consumption, and formula is following:
Rat dosage (mg/kg)=people's dosage (mg/kg) * 90% * (body weight for humans/Mus body weight)
1/3
Table 2 each treated animal number of elements and dosage
| Group | N | Dosage |
| Normal group | 10 | The 10ml/kgd distilled water |
| Model group | 14 | The 10ml/kgd distilled water |
| The Avandia group | 15 | 0.3mg/kg·d |
| Prescription 1 | 14 | 1.665g/kg·d |
| Prescription 2 | 14 | 1.565g/kg·d |
| Prescription 3 | 15 | 1.665g/kg·d |
Medicaments compound decocts once 7 weeks of successive administration every day.
2.5 experimental index is measured
Every day the observation experiment rat state;
Survey body weight weekly one time, a 24h food ration;
Per two weeks are done a metabolism, survey food ration amount of drinking water, voided volume, feces volume and anus temperature;
The blood serum sample preparation: after 7 weeks of administration, fasting 12h, the rat of weighing earlier; With the etherization experimental rat, the eye socket vein is got blood 4ml, leaves standstill 30min afterwards; The centrifugal 10min separation of serum of 3500r/min is sub-packed in blood serum sample in the PCR pipe of 12 parts of 0.2ml each 100 μ l;-80 ℃ of preservations are subsequent use to detect each index, and each index is measured according to product description.
Tissue sample preparation and preservation: when experiment finishes, get liver, left kidney, normal saline flushing, filter paper blot weighs, and calculates organ coefficient; Get hepatomegaly leaf four segments and encase with tinfoil, FFA and hepatic glycogen are measured in-80 ℃ of freezing confessions, get rat thigh skeletal muscle and encase with tinfoil, and muscle glycogen is measured in-80 ℃ of freezing confessions.With the heart, liver, kidney, pancreas, with 10% formalin fixed, HE dyeing is observed down with Zeiss (Axiostar Plus) optical microscope.
Body fat ratio: weigh before putting to death animal, behind the execution animal, get epididymis other fat and bilateral perirenal fat and weigh,, be prone to cause resultant error, so this experiment interior fat does not count because of fat on the mesentery is difficult clean from the intestinal separation.Body fat ratio=(the other fat weight of epididymis+perirenal fat weight)/rat body weight * 100%.
Liver tissue homogenate's preparation: take by weighing the frozen hepatic tissue of 200mg, add 2ml PBS, homogenate in the ice bath, the centrifugal 20min of 3500r/min carefully collects supernatant, detects the TG and the FFA content of hepatic tissue with the biochemical reagents box.
2.6 statistical method
Use the SPSS16.0 statistical software to carry out data analysis and figure output.Data are all used mean ± standard
expression.Each factor adopts single factor variance and t check.
3 experimental results
3.1 overview situation
The rats in normal control group mental status is good, and fur is glossy, and body weight rises continually and steadily.The type 2 diabetes mellitus rat is during administration, and body weight gain is slow, bradykinesia, and slow movement, fur tarnishes.Prescription 3, Avandia group respectively have one because of the too high death of blood glucose.Diabetes rat is except prescription 2, and each group all has 1-2 only because of the otitis media death of becoming thin.
3.2 diabetes rat " three-many-one-little " is estimated
During the administration, significantly " polydipsia, polyphagia, polyuria " symptom appears in diabetes rat, and the food ration of administration group rat is lower than model group basically, and amount of drinking water and urine amount and model group difference are little, and the anus temperature is a little more than model group, but the equal not statistically significant of difference.
3.3 body weight change situation during the administration
During the administration: the body weight gain of model group is slow than administration group and normal group, but not statistically significant.Around the administration, the body weight of model group obviously reduces (P＜0.05) than normal group; Prescription 2 is faster than other diabetes rats with the body weight gain of Avandia group, and the body weight gain trend and the model group of prescription 1 and prescription 3 are more or less the same, all not statistically significant (seeing table 3).
The body weight change of experimental rat during table 3 administration
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
3.4 the change of blood sugar of experimental rat
The fasting blood glucose level (
mmol/L) of experimental rat before and after table 4 administration
| Group | N | Before the administration | After the administration |
| Normal group | 8 | 5.9±0.35 | 5.4±0.20 |
| Model group | 8 | 14.4±2.39** | 20.7±3.66** |
| The Avandia group | 8 | 14.7±2.30 | 12.8±2.56# |
| Prescription 1 | 8 | 12.7±2.39 | 20.1±5.42 |
| Prescription 2 | 10 | 13.5±2.99 | 12.6±2.97# |
| Prescription 3 | 8 | 14.1±2.26 | 18.1±4.88 |
Annotate: compare with normal group: * * representes P＜0.01; Compare with model group: # representes P＜0.05.
Before the administration, the fasting blood glucose level of diabetes rat (FPG) is apparently higher than normal group (P＜0.01).In 8 weeks after the modeling, model group is still apparently higher than normal group (P＜0.01); Compare with model group, prescription 2 treatments 8 week back blood glucose have obvious decline (P＜0.05).
3.5 the organ coefficient of treatment back experimental rat
Table 5 shows, normal rats liver, scarlet, the smooth surface of kidney perusal color, and the liver surface of diabetes rat has slight or tangible lipochondrion shape, and the kidney volume is bigger.The kidney coefficient of diabetes rat and compared with normal have utmost point significant difference (P＜0.05 or P＜0.01), and the liver coefficient is bigger than normal, but difference does not have significance.The dirty coefficient of the device of administration group is compared difference with model group is not had significance.
The organ coefficient of table 5 experimental rat
| Group | N | Kidney coefficient (%) | Liver coefficient (%) | Body fat is than (%) |
| Normal group | 8 | 0.30±0.03 | 2.38±0.22 | 1.91±0.61 |
| Model group | 8 | 0.39±0.05* | 2.93±0.59 | 2.22±0.54 |
| The Avandia group | 8 | 0.39±0.06 | 3.02±0.59 | 2.60±0.62 |
| Prescription 1 | 8 | 0.42±0.04 | 3.39±0.37 | 1.87±0.52 |
| Prescription 2 | 10 | 0.40±0.06 | 2.99±0.35 | 1.42±0.40 |
| Prescription 3 | 8 | 0.40±0.08 | 3.13±0.41 | 2.01±0.93 |
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
3.6 influence to hepatic glycogen and muscle glycogen
Table 6 shows, the hepatic glycogen content of model group and prescription 1 is than normal group obviously raise (P＜0.01); With model contrast, the hepatic glycogen content of administration group all has reduction, especially with Avandia group the most obviously (P＜0.05).With compared with normal, the content of the muscle glycogen of diabetes rat all has rising, and the muscle glycogen content of administration group all has reduction than model group, but the equal not statistically significant of difference.
The hepatic glycogen and the muscle glycogen level
of table 6 treatment back experimental rat
| Group | N | Hepatic glycogen (mg/g) | Muscle glycogen (mg/g) |
| Normal group | 8 | 6.49±3.22 | 1.33±0.28 |
| Model group | 8 | 32.18±12.35** | 2.03±0.56 |
| The Avandia group | 8 | 13.86±7.55# | 1.77±0.65 |
| Prescription 1 | 8 | 40.23±6.61 | 1.50±0.46 |
| Prescription 2 | 10 | 17.42±9.99 | 1.79±0.33 |
| Prescription 3 | 8 | 16.25±12.45 | 1.91±0.64 |
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
3.7 influence to the lipid metabolism index
TG, the FFA level
of table 7 treatment back experimental rat serum TG, TC and liver tissue homogenate
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
Can find out from table 7, with normal group contrast, the TG content of model group serum, hepatic tissue obviously raise (P＜0.01).With the model group contrast, the serum TG of administration group and TC content are not seen remarkable reduction; But hepatic tissue TG, FFA all have obvious decline, with prescription 2 flat effects obvious (P＜0.01).
Two, 2 couples of INS of prescription, TNF-α, the influence of endotoxin and cyclic nucleotide
1 material
1.1 sample
-80 ℃ of frozen serum of normal group, model group, Avandia group and prescription 2
1.2 key instrument and reagent
RT-2100C ELIASA (Five continents, Beijing east development in science and technology company limited);
The accurate pipettor (10 μ l-100 μ l, 100 μ l-1000 μ l) of big dragon;
Vortex mixer (the special Analytical Instrument Co., Ltd of Shanghai fine jade);
-80 ℃ of ultra cold storage freezers (SANYO);
Hot water constant temperature groove (Shanghai Yiheng Scientific Instruments Co., Ltd);
The ELISA test kit (INS, TNF-α, ET, cAMP cGMP) all purchases the company in R&D.
2 experimental techniques
2.1 sample detection
According to ELISA test kit description to normal group, model group, Avandia group and prescription 2 rat blood serum INS, TNF-α, ET, cAMP, indexs such as cGMP detect.
2.2 statistical method
Use the OriginPro8.1 statistical software to carry out data analysis.Data are all used mean ± standard deviation
expression, and each factor adopts single factor variance and t check.
3 results
3.1 influence to diabetes rat serum fasting glucose (FPG), insulin (INS) and insulin sensitivity index (ISI)
Find out that from table 8 with the normal group contrast, the FPG and the ISI of model group significantly reduces (P＜0.01).With model group contrast, the serum FPG level of prescription 2 significantly is lower than model group (P＜0.05), but the inclined to one side and model group comparing difference not statistically significant of INS, ISI value of 2 groups of prescriptions.
Table 8 is respectively organized rat treatment back serum FPG; INS, the value of ISI
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
3.2 to the TNF-α of diabetes rat serum and the content influence of ET
From table 9, find out, with normal group contrast, blood serum tumor necrosis factor-alpha of model group (TNF-α) and endotoxin (ET) level significantly raise (P＜0.01).With the model group contrast, the serum TNF-alpha levels of prescription 2 obviously reduces (P＜0.05), and the Serum ET level is on the low side, but the difference not statistically significant.
Table 9 is respectively organized rat treatment back serum TNF-α and ET level
| N | TNF-α(mmol/L) | ET(ngl/L) |
| (ng/L) | (EU/L) | ||
| Normal group | 8 | 2.26±0.47 | 3.03±0.53 |
| Model group | 9 | 9.13±2.19** | 5.46±0.85** |
| The Avandia group | 9 | 6.98±1.05 | 6.50±1.33 |
| Prescription 2 | 9 | 5.89±2.34# | 4.92±1.02 |
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
3.3 to obese rat serum cAMP, the influence of cGMP level and cAMP/cGMP
Table 10 is respectively organized rat treatment back cAMP, cGMP level and cAMP/cGMP ratio
Annotate: compare with normal group: * representes P＜0.05, and * * representes P＜0.01; Compare with model group: # representes P＜0.05, and ## representes P＜0.01.
Table 10 result shows that with the normal group contrast, model group serum cAMP level, cGMP level and cAMP/cGMP ratio descend, but the difference not statistically significant.With the model group contrast, the cGMP level of prescription 2 significantly raises (P＜0.05), and cAMP/cGMP ratio is higher than model group, but the difference not statistically significant.
4 discuss
4.1 to FPG, the influence of INS and ISI
The part beta Cell of islet of STZ injury rats, hypoinsulinism hyperamization sugar raises.The blood sugar increasing of display model group is because serum insulin relative deficiency and the low coefficient result of insulin sensitivity in this result of study; In conjunction with sick inspection; Prescription 2 part islets of langerhans hypertrophy; Explain that this compound recipe maybe be through improving islet function promoting insulin secretion, thereby blood sugar lowering improves insulin resistant.
4.2 influence to TNF-α and ET
TNF-α is the excretory a kind of cytokine of activated mononuclear phagocyte and adipose cell, has wide biological activity.TNF-α mainly activates color/threonine (Ser/Thr) kinases through different paths, and the conduction of interfere with insulin signal influences signal transduction pathway behind the receptor, finally causes peripheral insulin resistance [142].Serum TNF-the α of diabetes rat is higher than normal rat in this test, and the serum TNF-α of prescription 2 obviously reduces than model group, and prompting heat clearing away compound recipe can reduce the generation of TNF-α, reduces inflammatory reaction, improves insulin resistant.
The serum level of endotoxin of diabetes rat raises than the normal group significance in this research; Serum endotoxin than front experiment obese rat is high; This prompting rat through high lipid food cause fat the reason of fat opposing be possible since in the body intestinal microbial population structure kind more, the lot of consumption energy; The level of endotoxin of prescription 2 is on the low side in model group, and prompting prescription 2 has the endotoxic ability of removing and plays the anti inflammatory detoxication effect.
4.3 to cAMP, the influence of cGMP level and cAMP/cGMP
Different pattern of syndrome person cyclic nucleotides change has certain rule, can assist the Chinese medical discrimination typing.The cAMP of model group rat in this research, cGMP level and cAMP/cGMP all are lower than normal rat, and the intense heat due to deficiency of YIN type possibly appear in the prompting diabetes rat, and diabetes rat possibly improve basal metabolism through rising cAMP/cGMP ratio after prescription 2 treatments.
In a word, prescription 2 can suppress blood glucose in diabetic rats and hepatic glycogen raises, and improves the TG and the FFA level of liver, improves carbohydrate tolerance, alleviates the lesion degree of the heart, liver and pancreas, downward modulation proinflammatory factor and level of endotoxin.This diabetes rat Long-term High-fat high-carbonhydrate diet, sugar can be given birth to heat, given birth to expectorant, and fat can be given birth to heat, property is held concurrently to be bored with and stagnated, so high glucose and high fat belongs to pyretic toxicity, expectorant poison, turbid poison, exist then to be stasis of blood poison in the blood.Many in recent years experiments and clinical data all point out diabetes often to exist cell infiltration and cytokine, inflammatory mediator level to rise.And inflammatory factor belongs to the category of Chinese medicine " poison of interior life ".In conjunction with modern clinical, it is closely related to think that diabetes are discussed modern pathology physiological Foundations and free radical toxicity, inflammatory cytokine toxicity and the high glucose and high fat toxicity its pathogenic process controlled from " poison ".In this research; It is main that prescription of the present invention is formed with Herba Bidentis Bipinnatae, berberine; Research report Herba Bidentis Bipinnatae has blood sugar lowering, blood fat reducing, anti-inflammatory and analgesic effect; Berberine has pharmacological actions such as transferring blood fat, blood sugar lowering, resisting myocardial ischemia, inhibition myocardial fibrosis, blood pressure lowering, antiplatelet, thus ourly aspect blood sugar lowering, have a significant effect, and can improve liver lipid metabolism.
Three, preparation embodiment
Embodiment 1
Pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2g, berberine 0.2g, Radix Salviae Miltiorrhizae 4g, Radix Notoginseng 2g, Bombyx Batryticatus powder 0.6g, Rhizoma Atractylodis 3g, Rhizoma Zingiberis 2g, Cortex Cinnamomi 0.75g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 2
Pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 9g, berberine 1g, Radix Salviae Miltiorrhizae 8g, Radix Notoginseng 4g, Bombyx Batryticatus powder 4g, Rhizoma Atractylodis 7g, Rhizoma Zingiberis 6g, Cortex Cinnamomi 4g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 3
Pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 6g, berberine 0.4g, Radix Salviae Miltiorrhizae 6g, Radix Notoginseng 2g, Bombyx Batryticatus powder 3g, Rhizoma Atractylodis 5g, Rhizoma Zingiberis 4g, Cortex Cinnamomi 0.8g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 4
Herba Bidentis Bipinnatae 600g, berberine 45g, Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g, Bombyx Batryticatus powder 90g, Rhizoma Atractylodis 250g weight portion, Rhizoma Zingiberis 250g, Cortex Cinnamomi 90g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 5
Pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 250g, berberine 15g, Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g, Bombyx Batryticatus powder 245g, Rhizoma Atractylodis 550g, Rhizoma Zingiberis 250g, Cortex Cinnamomi 90g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 6
Pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 260g, berberine 15g, Radix Salviae Miltiorrhizae 460g, Radix Notoginseng 140g, Bombyx Batryticatus powder 85g, Rhizoma Atractylodis 245g, Rhizoma Zingiberis 650g, Cortex Cinnamomi 270g.
Said medicine is that feedstock production becomes tablet, capsule, granule, oral liquid, mixture or pill.
Said embodiment includes but not limited to above-mentioned.
Claims (9)
1. pharmaceutical composition, it is characterized in that: pharmaceutical composition is made up of following raw material: Herba Bidentis Bipinnatae, berberine, Radix Salviae Miltiorrhizae, Radix Notoginseng, Bombyx Batryticatus powder, Rhizoma Atractylodis, Rhizoma Zingiberis and Cortex Cinnamomi.
2. a kind of pharmaceutical composition according to claim 1, pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-10 weight portion, berberine 0.1-1 weight portion; Radix Salviae Miltiorrhizae 3-10 weight portion; Radix Notoginseng 1-5 weight portion, Bombyx Batryticatus powder 0.5-5 weight portion, Rhizoma Atractylodis 1-8 weight portion; Rhizoma Zingiberis 1-8 weight portion, Cortex Cinnamomi 0.5-5 weight portion.
3. according to each described a kind of pharmaceutical composition of claim 1-2, pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 5-7 weight portion, berberine 0.4-0.5 weight portion; Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion; Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
4. according to each described a kind of pharmaceutical composition of claim 1-2, pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion; Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 2-3 weight portion, Rhizoma Atractylodis 5-7 weight portion; Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
5. according to each described a kind of pharmaceutical composition of claim 1-2, pharmaceutical composition is made up of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion; Radix Salviae Miltiorrhizae 4-5 weight portion; Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion; Rhizoma Zingiberis 5-7 weight portion, Cortex Cinnamomi 2-3 weight portion.
6. become oral formulations according to each described a kind of preparation of pharmaceutical compositions of claim 1-5.
7. according to the application of each described a kind of pharmaceutical composition of claim 1-5 in preparation treatment high blood cholesterol drug.
8. according to the application of each described a kind of pharmaceutical composition of claim 1-5 in the medicine of preparation treatment diabetes.
9. a kind of preparation of pharmaceutical compositions according to claim 6 becomes oral formulations, and wherein oral formulations comprises tablet, capsule, granule, oral liquid, mixture or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210024378.6A CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210024378.6A CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552852A true CN102552852A (en) | 2012-07-11 |
| CN102552852B CN102552852B (en) | 2014-01-15 |
Family
ID=46400305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210024378.6A Expired - Fee Related CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552852B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605354A (en) * | 2015-01-27 | 2015-05-13 | 广西大学 | Health nutrient powder of altemanthera and preparation method of health nutrient powder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316275A (en) * | 2000-04-04 | 2001-10-10 | 徐代科 | Antihypertensive medicinal pillow |
| CN102274482A (en) * | 2011-08-19 | 2011-12-14 | 张丙焕 | Chinese medicinal preparation for treating diabetes |
-
2012
- 2012-02-03 CN CN201210024378.6A patent/CN102552852B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316275A (en) * | 2000-04-04 | 2001-10-10 | 徐代科 | Antihypertensive medicinal pillow |
| CN102274482A (en) * | 2011-08-19 | 2011-12-14 | 张丙焕 | Chinese medicinal preparation for treating diabetes |
Non-Patent Citations (2)
| Title |
|---|
| 何岚等: "中药肉桂降血糖、降血脂作用的研究进展", 《中国现代中药》, vol. 10, no. 8, 31 August 2008 (2008-08-31), pages 8 - 11 * |
| 曾英等: "中药食疗对肥胖2型糖尿病患者血糖及血脂的影响", 《广西医学》, vol. 28, no. 2, 28 February 2006 (2006-02-28), pages 199 - 201 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605354A (en) * | 2015-01-27 | 2015-05-13 | 广西大学 | Health nutrient powder of altemanthera and preparation method of health nutrient powder |
| CN104605354B (en) * | 2015-01-27 | 2016-06-01 | 广西大学 | A kind of shrimp claw plant health care nutrition powder and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552852B (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Hypoglycemic effects and modulation of gut microbiota of diabetic mice by saponin from Polygonatum sibiricum | |
| Wang et al. | Semi-bionic extraction of compound turmeric protects against dextran sulfate sodium-induced acute enteritis in rats | |
| CN110833595B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN103110697A (en) | Pharmaceutical composition with hypoglycemic effect | |
| CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
| CN107073060B (en) | Aqueous extracts of cinnamon and astragalus | |
| CN102552852B (en) | Pharmaceutical composition and use thereof | |
| CN103736071A (en) | Composition having effect of assisting in decreasing blood sugar, and application and preparation method thereof | |
| CN102526672B (en) | Traditional Chinese medicine composition, applications and preparation method | |
| CN101829271B (en) | Chinese medicinal compound with function of treating diabetes and preparation method and application thereof | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN106822095A (en) | A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| CN101181349B (en) | Application of Salvia przewalskii Maxim extract in the preparation of medicament for curing nephritis of renal glomerulus | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN100525804C (en) | Chinese traditional medicine compound preparations having a function of slimming | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN100336526C (en) | Medicine composition for treating diabetes and preparing method | |
| CN104208210B (en) | A kind of Chinese medicine composition treating insulin resistant and relevant disease and preparation method thereof and Chinese medicine preparation | |
| Ping et al. | Research progress on the mechanism of TCM regulating intestinal microbiota in the treatment of DM mellitus | |
| CN102430001A (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN102335362A (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| Zou | Research of antiphlogistic and analgesic properties of American ginsengng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140115 Termination date: 20200203 |